The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health
The emergence of the COVID-19 JN.1 variant has raised global health concerns as it gains prevalence in several regions worldwide. First identified in August 2023, JN.1 evolved from the Omicron lineage’s BA.2.86 subvariant. Patients infected with JN.1 commonly exhibit symptoms such as sore throat, fe...
Saved in:
Main Authors: | Araj Naveed Siddiqui, Imshaal Musharaf, Bashar Haruna Gulumbe |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Infectious Disease |
Online Access: | https://doi.org/10.1177/20499361251314763 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Fortifying defenses: Tactical safety protocols for COVID-19 sub-variant JN.1 in healthcare and laboratory settings
by: Shazima Sheereen, et al.
Published: (2025-01-01) -
Virus Immune Evasion: New Mechanism and Implications in Disease Outcome
by: Rika Draenert, et al.
Published: (2012-01-01) -
Immune Evasion Strategies of Trypanosoma cruzi
by: Ana Flávia Nardy, et al.
Published: (2015-01-01) -
NF-κB signaling and the tumor microenvironment in osteosarcoma: implications for immune evasion and therapeutic resistance
by: Shaoyan Shi, et al.
Published: (2025-01-01) -
Trogocytosis-mediated immune evasion in the tumor microenvironment
by: Jeonghyun Kim, et al.
Published: (2025-01-01)